Biotech RadarJobs updated

COMPANY

ProQR Therapeutics

HQ: Leiden, Netherlands source · proqr.com ↗ · Europe

Clinical Phase 3

8 open jobs · last seen Oct 23, 2026 · 10 sources

Profile checked Oct 10, 2026

Keywords: Eye Diseases Hereditary Eye Diseases Retinal Disease Vision Disorders Eye Disorders Congenital Retinal Dystrophies Leber Congenital Amaurosis 10 Blindness Leber Congenital Amaurosis Sensation Disorders Neurologic Manifestations Cystic Fibrosis Fuchs Endothelial Corneal Dystrophy FECD3 Corneal Diseases Descemet's Membrane Disorder Autosomal Dominant Retinitis Pigmentosa Retinitis Vision Tunnel Retinitis Pigmentosa Usher Syndrome Type 2 Deaf Blind Retinal Degeneration sepofarsen QR-010 QR-504a QR-1123 QR-421a

8+1 patient-care hiddenOpen jobs$113.0MRaised (2 yrs)7Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Director Regulatory AffairsLeiden, NetherlandsOct 12, 2026Oct 14, 2026
Manager / Associate Director Regulatory Affairs Operations & SubmissionsLeiden, NetherlandsOct 12, 2026Oct 14, 2026
Assistant FacilitiesLeiden, NetherlandsOct 1, 2026Oct 11, 2026
Research Technician Protein AssaysLeiden, NetherlandsOct 1, 2026Oct 11, 2026
Associate Research TechnicianLeiden, NetherlandsSep 29, 2026Oct 11, 2026

See all 8 jobs

Timeline

  1. Raise Follow-on offering — Registered direct: $50M (total, as published), announced Jun 25, 2026. Source: company's own press page. source ↗
  2. Partnership Partnership / licensing: upfront not published; stated deal value $8.1M (kept separate from upfront), announced Dec 11, 2024. Source: company's own press page. source ↗
  3. Raise Follow-on offering: $63M (total, as published), announced Oct 25, 2024. Source: company's own press page. source ↗
  4. Trial start Phase 1: Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 source ↗
  5. Trial start Phase 2/Phase 3: An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Muta source ↗
  6. Trial start Phase 1/Phase 2: A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene source ↗
  7. Trial start Phase 2/Phase 3: A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) source ↗
  8. Trial start Phase 1/Phase 2: Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene source ↗
  9. Trial start Phase 1: Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation source ↗
  10. Trial start Phase 1/Phase 2: Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients source ↗

Funding

Raised: $113.0M. Last 2 years.

Clinical trials (lead sponsor) 7

RecordTitlePhaseStatusStartPrimary completion
NCT05052554Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3Phase 1WithdrawnAug 10, 2021Apr 12, 2022 (actual)
NCT04123626A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO GenePhase 1/Phase 2Active, not recruitingOct 7, 2019Jun 7, 2022 (estimated)
NCT03780257Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A GenePhase 1/Phase 2CompletedMar 6, 2019Oct 14, 2021 (actual)
NCT04855045An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.Phase 2/Phase 3Unknown status (ClinicalTrials.gov)Mar 23, 20212023-12 (estimated)
NCT03913143A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)Phase 2/Phase 3Active, not recruitingApr 4, 2019Jan 31, 2022 (actual)
NCT02564354Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR MutationPhase 1Completed2015-092016-09 (actual)
NCT02532764Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis PatientsPhase 1/Phase 2Completed2015-06Sep 14, 2017 (actual)

Open jobs 8

1 patient-care job hidden (phlebotomy, plasma-center, nursing and similar care roles; 9 open jobs in total).

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Director Regulatory AffairsLeiden, NetherlandsOct 12, 2026Oct 14, 2026Not stated
Manager / Associate Director Regulatory Affairs Operations & SubmissionsLeiden, NetherlandsOct 12, 2026Oct 14, 2026Not stated
Assistant FacilitiesLeiden, NetherlandsOct 1, 2026Oct 11, 2026Not stated
Research Technician Protein AssaysLeiden, NetherlandsOct 1, 2026Oct 11, 2026Not stated
Associate Research TechnicianLeiden, NetherlandsSep 29, 2026Oct 11, 2026Not stated
Clinical Operations LeadLeiden, NetherlandsAug 20, 2026Oct 11, 2026Not stated
Associate Director BiostatisticsLeiden, NetherlandsJul 22, 2026Oct 11, 2026Not stated
Director ToxicologyLeiden, NetherlandsJul 17, 2026Oct 11, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at ProQR Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback